Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RDNT Stock Forecast 2026-2027
$72.90
Current Price
$5.63B
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RDNT Price Targets
+34.4%
To High Target of $98.00
+25.5%
To Median Target of $91.50
+18.0%
To Low Target of $86.00
RDNT Price Momentum
-7.0%
1 Week Change
+0.4%
1 Month Change
+18.1%
1 Year Change
+2.2%
Year-to-Date Change
-15.1%
From 52W High of $85.84
+62.0%
From 52W Low of $45.00
📊 TOP ANALYST CALLS
Did RDNT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if RadNet is one of their latest high-conviction picks.
Latest RDNT Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, RDNT has a bullish consensus with a median price target of $91.50 (ranging from $86.00 to $98.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $72.90, the median forecast implies a 25.5% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Andrew Mok at Barclays, suggesting a 18.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RDNT Analyst Ratings
8
Buy
0
Hold
0
Sell
RDNT Price Target Range
Low
$86.00
Average
$91.50
High
$98.00
Current: $72.90
Latest RDNT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RDNT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | Keybanc | Matthew Gillmor | Overweight | Initiates | $92.00 |
| Dec 1, 2025 | B. Riley Securities | Yuan Zhi | Buy | Maintains | $87.00 |
| Nov 13, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $86.00 |
| Nov 12, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $90.00 |
| Sep 3, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $81.00 |
| Sep 3, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $79.00 |
| Aug 13, 2025 | Raymond James | John Ransom | Strong Buy | Reiterates | $75.00 |
| Jun 13, 2025 | B. Riley Securities | Yuan Zhi | Buy | Initiates | $69.00 |
| Apr 11, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $74.00 |
| Mar 24, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $60.00 |
| Mar 5, 2025 | Raymond James | John Ransom | Strong Buy | Upgrade | $65.00 |
| Jan 22, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $74.00 |
| Jan 22, 2025 | Truist Securities | David Macdonald | Buy | Reiterates | $88.00 |
| Jan 15, 2025 | Jefferies | Brian Tanquilut | Buy | Maintains | $80.00 |
| Dec 5, 2024 | Jefferies | Brian Tanquilut | Buy | Maintains | $100.00 |
| Dec 4, 2024 | Barclays | Andrew Mok | Overweight | Maintains | $85.00 |
| Nov 29, 2024 | Truist Securities | David Macdonald | Buy | Maintains | $94.00 |
| Sep 23, 2024 | Truist Securities | David Macdonald | Buy | Maintains | $80.00 |
| Sep 19, 2024 | Jefferies | Brian Tanquilut | Buy | Maintains | $80.00 |
| Sep 6, 2024 | Barclays | Andrew Mok | Overweight | Upgrade | $79.00 |
RadNet Inc. (RDNT) Competitors
The following stocks are similar to RadNet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RadNet Inc. (RDNT) Financial Data
RadNet Inc. has a market capitalization of $5.63B with a P/E ratio of 1,425.8x. The company generates $1.97B in trailing twelve-month revenue with a -0.6% profit margin.
Revenue growth is +13.4% quarter-over-quarter, while maintaining an operating margin of +6.7% and return on equity of +1.8%.
Valuation Metrics
Market Cap
$5.63B
Enterprise Value
$7.19B
P/E Ratio
1,425.8x
PEG Ratio
19.0x
Price/Sales
2.9x
Growth & Margins
Revenue Growth (YoY)
+13.4%
Gross Margin
+13.9%
Operating Margin
+6.7%
Net Margin
-0.6%
EPS Growth
+68.8%
Financial Health
Cash/Price Ratio
+14.3%
Current Ratio
1.9x
Debt/Equity
140.6x
ROE
+1.8%
ROA
+1.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
RadNet Inc. (RDNT) Business Model
About RadNet Inc.
What They Do
Provides outpatient diagnostic imaging services.
Business Model
RadNet operates a network of imaging centers offering MRI, CT scans, mammography, ultrasound, and nuclear medicine. The company generates revenue by providing these diagnostic services directly to patients and healthcare providers, focusing on cost-effective solutions outside traditional hospital settings.
Additional Information
RadNet's role in healthcare is critical, especially in oncology, cardiology, and women's health, as it supports early detection and treatment planning. The company is also investing in artificial intelligence and data analytics to enhance diagnostic accuracy and operational efficiency, making it a key player in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
11,000
CEO
Dr. Howard G. Berger M.D.
Country
United States
IPO Year
1997
Website
www.radnet.comRadNet Inc. (RDNT) Latest News & Analysis
Latest News
RadNet, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026
6 days ago
Quick Summary
RadNet, Inc. (NASDAQ: RDNT) executives will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 10:30 a.m. PST in San Francisco.
Why It Matters
RadNet's participation in a major healthcare conference highlights its strategic position and potential growth, influencing investor perception and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
RadNet, Inc. (NASDAQ: RDNT) has acquired Radiology Regional, expanding its services to 13 locations in Southwest Florida, enhancing its outpatient diagnostic imaging offerings.
Why It Matters
RadNet's acquisition of Radiology Regional expands its market presence in Florida, potentially increasing revenue and enhancing operational efficiency, which could positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
RadNet, Inc. (NASDAQ: RDNT) shares dropped following a short report from Hunterbrook Capital, criticizing smaller firms for misleadingly inflating valuations with "AI" claims.
Why It Matters
RadNet's stock decline following a short report signals potential risks and skepticism about its valuation amid AI hype, which could affect investor confidence and future performance.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
DeepHealth, a subsidiary of RadNet, Inc. (Nasdaq: RDNT), announced an expanded portfolio of AI-driven imaging informatics at RSNA 2025, enhancing disease detection and clinical operations.
Why It Matters
DeepHealth's advancements in AI imaging solutions could enhance operational efficiency and improve patient outcomes, potentially increasing RadNet's market share and profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
DeepHealth Launches Breast Suite, Elevating Breast Cancer Detection, Risk Stratification and Workflow
1 month ago
Quick Summary
DeepHealth, a subsidiary of RadNet, launched the Breast Suite, an AI-powered application suite enhancing mammogram detection and workflow for breast cancer screening.
Why It Matters
The launch of DeepHealth's Breast Suite enhances mammogram efficiency and detection rates, potentially increasing market share and revenue for RadNet, thus impacting its stock valuation positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A comprehensive study in the US shows that AI-driven breast cancer screening improves detection rates and provides consistent results across diverse patient groups.
Why It Matters
Increased cancer detection rates from AI-driven screening can lead to higher demand for related healthcare technologies, potentially boosting stock prices of companies in this sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RDNT Stock
What is RadNet Inc.'s (RDNT) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, RadNet Inc. (RDNT) has a median price target of $91.50. The highest price target is $98.00 and the lowest is $86.00.
Is RDNT stock a good investment in 2026?
According to current analyst ratings, RDNT has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $72.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RDNT stock?
Wall Street analysts predict RDNT stock could reach $91.50 in the next 12 months. This represents a 25.5% increase from the current price of $72.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is RadNet Inc.'s business model?
RadNet operates a network of imaging centers offering MRI, CT scans, mammography, ultrasound, and nuclear medicine. The company generates revenue by providing these diagnostic services directly to patients and healthcare providers, focusing on cost-effective solutions outside traditional hospital settings.
What is the highest forecasted price for RDNT RadNet Inc.?
The highest price target for RDNT is $98.00 from at , which represents a 34.4% increase from the current price of $72.90.
What is the lowest forecasted price for RDNT RadNet Inc.?
The lowest price target for RDNT is $86.00 from Andrew Mok at Barclays, which represents a 18.0% increase from the current price of $72.90.
What is the overall RDNT consensus from analysts for RadNet Inc.?
The overall analyst consensus for RDNT is bullish. Out of 9 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $91.50.
How accurate are RDNT stock price projections?
Stock price projections, including those for RadNet Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:06 AM UTC